Ranbaxy is the subject of a Class 2
Drug Alert by the UK Medicines
and Healthcare products
Regulatory Agency over the product
information included in batches of
its Mirtazapine 15mg tablets.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 14 May 10 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 May 10
LEADING pharmacy, consumer and Federal agencies want to see better use of existing funding and leverage digital health resources to improve quality use of medicines, discussions at the Medicines Safety Forum in Canberra revealed.